Skip to main content

Table 1 Patient characteristics and their comparison among subgroups by WBRT dose

From: Relationship between WBRT total dose, intracranial tumor control, and overall survival in NSCLC patients with brain metastases - a single-center retrospective analysis

VariablesWBRT Dose All
None< 30Gy30-39Gy≥40Gy
(n1 = 344)(n2 = 30)(n3 = 93)(n4 = 128)(N = 595)
n(%)n(%)n(%)n(%)paN(%)
Sex
 female159 (46.2)14 (46.7)30 (32.3)56 (43.8)0.114259 (43.5)
 male185 (53.8)16 (53.3)63 (67.7)56 (56.2) 336(56.5)
CVD146 (42.4)18 (60.0)40 (43.0)53 (41.4)ns257 (43.2)
Age (years)
 <5061 (17.7)3 (10.0)13 (14.0)25 (19.5)0.115102 (17.1)
 50–59104 (30.2)8 (26.7)36 (38.7)52 (40.6) 200 (33.6)
  ≥ 60179 (52.6)19 (63.3)44 (47.3)51 (39.8) 293 (49.2)
KPS
  < 7086 (25.0)13 (43.3)37 (39.8)54 (42.2)< 0.001190 (31.9)
 70–8077 (22.4)7 (23.3)35 (37.6)45 (35.2) 164 (27.6)
  ≥ 90181 (52.6)10 (33.3)21 (22.6)29 (22.7) 241 (40.5)
NSCLC history (month)
  < 1197 (57.3)12 (40.0)41 (44.1)51 (39.8)0.004301 (50.6)
 1–645 (13.1)5 (16.7)6 (6.5)22 (17.2) 78 (13.1)
 6–1245 (13.1)5 (16.7)17 (18.3)21 (16.4) 88 (14.8)
  > 1257 (16.6)8 (26.7)29 (31.2)34 (26.6) 128 (21.5)
BM lesion number
 1166 (48.3)11 (36.7)25 (26.9)36 (28.1) 238 (40.0)
 2–353 (15.4)7 (23.3)18 (19.4)22 (17.2) 100 (16.8)
  ≥ 4125 (36.3)12 (40.0)50 (53.8)70 (54.7) 257 (43.2)
Extracranial met.268 (77.9)19 (63.3)64 (68.8)84 (65.6)0.019435 (73.1)
Brain stem met.91 (2.4)1 (7.0)3 (3.2)3 (2.3)ns16 (2.7)
Meningeal met.25 (7.3)2 (6.7)2 (2.2)9 (7.0)ns43 (6.4)
Targeted therapy97 (28.2)9 (30.0)23 (24.7)39 (30.5)ns168 (28.2)
Chemotherapy173 (50.3)11 (36.7)43 (46.2)72 (56.3)0.199299 (50.3)
SRT14 (5.1)0 (0.0)0 (0.0)1 (0.8)0.06015 (2.5)
Local/boost RT (Gy)
 none325 (94.5)23 (76.7)15 (16.1)55 (43.0)< 0.001418 (73.0)
 <508 (2.3)6 (20.0)3 (3.2)6 (4.7) 23 (3.9)
 50–599 (2.6)1 (3.3)38 (40.9)42 (32.8) 90 (15.1)
  ≥ 602 (0.6)0 (0.0)37 (39.8)25 (19.5) 64 (10.8)
BM resection
 none326 (94.8)29 (96.7)90 (96.8)118 (92.2)ns563 (94.6)
 incomplete2 (0.7)0 (0.0)0 (0.0)2 (1.5) 4 (0.7)
 complete16 (4.7)1 (3.3)3 (3.2)8 (6.3) 28 (4.7)
Initial cTNM Stage IV274 (79.7)21 (70.0)55 (59.1)75 (58.6)< 0.001425 (71.4)
Lung tumor surgery
 none301 (87.5)23 (76.7)67 (72.0)90 (70.3)< 0.001481 (80.8)
 incomplete6 (1.7)3 (10.0)4 (4.3)11 (8.6) 24 (4.0)
 radical37 (10.8)4 (13.3)22 (23.7)27 (21.1) 90 (15.1)
 Adenocarcinoma242 (70.3)22 (73.3)66 (71.0)91 (71.1)ns421 (70.8)
EGFR mutation
 neg.55 (16.0)3 (10.0)23 (24.7)20 (15.6)ns101 (17.0)
 pos.74 (21.5)5 (16.7)13 (14.0)22 (17.2) 114 (19.2)
 no record215 (62.5)22 (73.3)57 (61.3)86 (67.2) 380 (63.9)
ALK mutation
 neg.15 (4.4)1 (3.3)3 (3.2)3 (2.3)0.06922 (3.7)
 pos.1 (0.3)2 (6.7)2 (2.2)1 (0.8) 6 (1.0)
 no record328 (95.3)27 (90.0)88 (94.6)124 (96.9) 567 (95.3)
  1. WBRT whole brain radiotherapy; CVD cardiovascular disease; ns not significant with p > 0.20; BM brain metastasis; KPS Karnofsky Performance Score; NSCLC non-small cell lung cancer; met. Metastases; SRT stereotactic radiotherapy; RT radiotherapy; EGFR epidermal growth factor receptor; neg. Negative; pos. Positive; ALK anaplastic lymphoma kinase.
  2. a from the Chi-square or Fisher’s exact (if applied) test.